Marine phospholipids—a promising new dietary approach to tumor-associated weight loss
- 314 Downloads
Goals of work
Advanced tumor disease very often evokes excessive loss of body weight. Among others, fish oil or marine fatty acid ethyl esters were investigated for treatment of cancer cachexia with controversial results. In this study, a new formulation of marine fatty acids was investigated, the marine phospholipids, with more than 50% of phospholipid-bound fatty acids being eicosapentaenoic and docosahexaenoic acid.
Materials and methods
Thirty-one tumor patients with various tumor entities suffering from weight loss were asked to take marine phospholipids (1.5 g/day) as softgel capsules for a period of 6 weeks. Compliance, body weight, appetite, and quality of life as well as the fatty acid profile in plasma and blood cells were monitored; 17 patients could be analyzed.
Marine phospholipids were very well accepted; low-dose supplementation resulted in a significant increase of eicosapentaenoic and docosahexaenoic acid in plasma phospholipids; therefore, significantly reducing the n − 6 to n − 3 fatty acid ratio. A stabilization of body weight was achieved (median weight change of +0.6% after 6 weeks), while appetite and quality of life improved.
These promising first results encourage further investigation of marine phospholipids in cancer care.
KeywordsMarine phospholipids Cancer Weight loss Marine fatty acids Lyso-phosphatidylcholine
We thank the Dietmar Hopp Stiftungs GmbH and Kirstins Weg e.V. for financial support. Thanks to all of our colleagues who supported the performance of this investigation.
Conflict of interest
The Tumor Biology Center Freiburg has applied for a patent pertaining to the use of marine phospholipids for palliative cancer treatment. The patent is intended to be commercialized. The presented investigation of marine phospholipids was funded in its entirety, including the purchase of the marine phospholipid formulation, by research sponsorship as stated in the acknowledgements section.
- 2.Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K (2003) Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 25:420–429. doi: 10.1016/S0885-3924(03)00074-5 CrossRefPubMedGoogle Scholar
- 16.Wigmore SJ, Fearon KC, Maingay JP, Ross JA (1997) Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 92:215–221Google Scholar
- 19.Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F (1998) Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 82:395–402. doi: 10.1002/(SICI)1097-0142(19980115)82:2<403::AID-CNCR21>3.0.CO;2-1 CrossRefPubMedGoogle Scholar
- 30.Oette K, Kuhn G, Romer A, Niemann R, Gundermann KJ, Schumacher R (1995) Arzneimittelforschung 45:875–879. Absorption of di-linoleoylphosphatidylcholine after oral administrationGoogle Scholar
- 31.Wijendran V, Huang MC, Diau GY, Boehm G, Nathanielsz PW, Brenna JT (2002) Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates. Pediatr Res 51:265–272. doi: 10.1203/00006450-200203000-00002 CrossRefPubMedGoogle Scholar
- 46.Raffelt K, Moka D, Sullentrop F, Dietlein M, Hahn J, Schicha H (2000) Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in-vitro (31) P high-resolution NMR study. NMR Biomed 13:8–13. doi: 10.1002/(SICI)1099-1492(200002)13:1<8::AID-NBM602>3.0.CO;2-X CrossRefPubMedGoogle Scholar
- 48.Boggs KP, Rock CO, Jackowski S (1995) Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 270:7757–7764. doi: 10.1074/jbc.270.13.7757 CrossRefPubMedGoogle Scholar
- 50.Balsinde J, Bianco ID, Ackermann EJ, Conde-Frieboes K, Dennis EA (1995) Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 92:8527–8531. doi: 10.1073/pnas.92.18.8527 CrossRefPubMedGoogle Scholar